Compare TWIN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | INBX |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 999.7M |
| IPO Year | 1994 | 2024 |
| Metric | TWIN | INBX |
|---|---|---|
| Price | $14.96 | $69.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 41.5K | ★ 136.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $340,738,000.00 | $200,000.00 |
| Revenue This Year | $10.79 | $563.00 |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $6.16 | $10.81 |
| 52 Week High | $19.63 | $94.57 |
| Indicator | TWIN | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 40.74 |
| Support Level | $14.80 | $28.54 |
| Resistance Level | $16.62 | $85.97 |
| Average True Range (ATR) | 0.84 | 4.31 |
| MACD | -0.34 | -0.65 |
| Stochastic Oscillator | 11.31 | 15.04 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.